We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about TransMedics (TMDX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, TransMedics (TMDX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.18 per share, reflecting an increase of 50% compared to the same period last year. Revenues are forecasted to be $110.38 million, representing a year-over-year increase of 36%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some TransMedics metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Net revenue by OCS product- OCS Lung net revenue' will reach $3.83 million. The estimate indicates a year-over-year change of +19.7%.
The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' stands at $76.93 million. The estimate indicates a change of +42% from the prior-year quarter.
It is projected by analysts that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $28.81 million. The estimate indicates a change of +38.5% from the prior-year quarter.
Analysts expect 'Geographic Revenues- United States' to come in at $108.16 million. The estimate suggests a change of +43.8% year over year.
Analysts forecast 'Geographic Revenues- All other countries' to reach $3.00 million. The estimate indicates a year-over-year change of -14.8%.
TransMedics shares have witnessed a change of +18.3% in the past month, in contrast to the Zacks S&P 500 composite's -0.5% move. With a Zacks Rank #3 (Hold), TMDX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about TransMedics (TMDX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
In its upcoming report, TransMedics (TMDX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.18 per share, reflecting an increase of 50% compared to the same period last year. Revenues are forecasted to be $110.38 million, representing a year-over-year increase of 36%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some TransMedics metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Net revenue by OCS product- OCS Lung net revenue' will reach $3.83 million. The estimate indicates a year-over-year change of +19.7%.
The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' stands at $76.93 million. The estimate indicates a change of +42% from the prior-year quarter.
It is projected by analysts that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $28.81 million. The estimate indicates a change of +38.5% from the prior-year quarter.
Analysts expect 'Geographic Revenues- United States' to come in at $108.16 million. The estimate suggests a change of +43.8% year over year.
Analysts forecast 'Geographic Revenues- All other countries' to reach $3.00 million. The estimate indicates a year-over-year change of -14.8%.
View all Key Company Metrics for TransMedics here>>>
TransMedics shares have witnessed a change of +18.3% in the past month, in contrast to the Zacks S&P 500 composite's -0.5% move. With a Zacks Rank #3 (Hold), TMDX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>